TargetMol

DA-7867

Product Code:
 
TAR-T23947
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T23947-5mg5mg£930.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23947-50mg50mg£1,821.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23947-100mg100mg£2,319.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
DA-7867 is a novel oxazolidinone. DA-7867 had the lowest MIC for 90% of the aerobic gram-positive bacterial strains tested (?0.25 μg/ml) and it was more potent than linezolid. DA-7867 was the most active drug with a MIC(90) of 0.125 μg/ml.
CAS:
380382-38-7
Formula:
C19H18FN7O3
Molecular Weight:
411.397
Purity:
0.98
SMILES:
CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(nc1)-c1nnnn1C

References

1. Vera-Cabrera L, Castro-Garza J, Rendon A, Ocampo-Candiani J, Welsh O, Choi SH, Blackwood K, Molina-Torres C. In vitro susceptibility of Mycobacterium tuberculosis clinical isolates to garenoxacin and DA-7867. Antimicrob Agents Chemother. 2005 Oct;49(10):4351-3. PubMed PMID: 16189119; PubMed Central PMCID: PMC1251498. 2. Yong D, Yum JH, Lee K, Chong Y, Choi SH, Rhee JK. In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 2004 Jan;48(1):352-7. Erratum in: Antimicrob Agents Chemother. 2004 May;48(5):1918. PubMed PMID: 14693566; PubMed Central PMCID: PMC310204. 3. Vera-Cabrera L, Brown-Elliott BA, Wallace RJ Jr, Ocampo-Candiani J, Welsh O, Choi SH, Molina-Torres CA. In vitro activities of the novel oxazolidinones DA-7867 and DA-7157 against rapidly and slowly growing mycobacteria. Antimicrob Agents Chemother. 2006 Dec;50(12):4027-9. Epub 2006 Oct 2. PubMed PMID: 17015632; PubMed Central PMCID: PMC1693997. 4. Vera-Cabrera L, Daw-Garza A, Said-Fern?ndez S, Lozano-Garza HG, de Torres NW, Rocha NC, Ocampo-Candiani J, Choi SH, Welsh O. Therapeutic effect of a novel oxazolidinone, DA-7867, in BALB/c mice infected with Nocardia brasiliensis. PLoS Negl Trop Dis. 2008 Sep 10;2(9):e289. doi: 10.1371/journal.pntd.0000289. PubMed PMID: 18820738; PubMed Central PMCID: PMC2553479.